Search

Author/Creator Bexon, Alice

1. 423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors. (10th December 2020)

Authors:
O'Day, Steven; Perez, Cesar; Wise-Draper, Trisha; Hanna, Glenn; Bhatia, Shailender; Kelly, Ciara; Medina, Theresa; Laux, Douglas; Daud, Adil; Chandra, Sunandana; Shaheen, Montaser; Gao, Ling; Burgess, Melissa; Hernandez-Aya, Leonel; Yeung, Cecilia; Smythe, Kimberly; DeGoma, Emil; Daniel, Weston; ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A257
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). (14th November 2022)

Authors:
Iwamoto, Fabio; Gondi, Vinai; Butowski, Nicholas; Falchook, Gerald; Williams, Anja; Peters, Katherine B; Evans, Jeff; Lakhani, Nehal; McKean, Meredith; Symeonides, Stefan; Ellingson, Benjamin; Rotolo, Jim; Capiaux, Gina; Wiegert, Erol; Michel, Rob; Kaesshaefer, Steve; Bexon, Alice
Journal:
Neuro-oncology
Issue:
Volume 24(2022)Supplement 7
Page Start:
vii83
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME. (12th November 2021)

Authors:
Symeonides, Stefan; Evans, Jeff; Arkenau, Hendrik-Tobias; McKean, Meredith; Lakhani, Nehal; Lim, Emerson; Falchook, Gerald; Rotolo, Jim; Capiaux, Gina; Michel, Rob; Kaesshaefer, Stephen; Bexon, Alice
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 6(2021)
Page Start:
vi71
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗